{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7"},{"groupId":"OG001","value":"13.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"title":"Day 15 to ≤ Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0"},{"groupId":"OG001","value":"33.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Day 29 to ≤ Day 42"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4"},{"groupId":"OG001","value":"41.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Day 43 to ≤ Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7"},{"groupId":"OG001","value":"47.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"title":"Day 57 to ≤ Day 70"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3"},{"groupId":"OG001","value":"51.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Day 71 to ≤ Day 84"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5"},{"groupId":"OG001","value":"54.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"Day 85 to ≤ Day 98"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2"},{"groupId":"OG001","value":"60.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"Day 99 to ≤ Day 112"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2"},{"groupId":"OG001","value":"66.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"title":"Day 113 to ≤ Day 126"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8"},{"groupId":"OG001","value":"68.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Day 127 to ≤ Day 140"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0"},{"groupId":"OG001","value":"68.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"120"}],"units":"Participants"}],"title":"Day 141 to ≤ Day 154"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6"},{"groupId":"OG001","value":"71.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Day 155 to ≤ Day 168"},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9"},{"groupId":"OG001","value":"88.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"title":"Day 169 to ≤ Day 182"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"description":"All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants with a ≥ 50% reduction in daily corticosteroid dose.","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"Safety Set: all participants who received at least one dose of study treatment. Participants were to have been analyzed according to the study treatment received, where treatment received was defined as the randomized treatment if the participant took at least one dose of that treatment or the first treatment received if the randomized treatment was never received. Six participants in the BAT arm discontinued before receiving the first dose. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"from Day 15 up to Day 182","title":"Percentage of Participants With a ≥ 50% Reduction in Daily Corticosteroid Dose","type":"SECONDARY","unitOfMeasure":"percentage of participants"}